Danish pharmaceutical company Novo Nordisk is pursuing legal action against two U.S.-based pharmacies for allegedly selling products claiming to contain semaglutide that are not approved by the U.S. Food and Drug Administration (FDA).
In a statement on Nov. 30, the drugmaker said it had conducted tests on compounded products allegedly sold by Wells Pharmacy and Brooksville Pharmaceuticals, two compounding pharmacies based in Florida.
